Key Takeaways:
Hong Kong-based Transcenta-B (06628.HK) said its partner, Inhibrx Biosciences (INBX.US), plans to file for U.S. regulatory approval for the cancer treatment ozekibart by April 2026 following positive new clinical data.
The plan was part of an announcement by Inhibrx detailing positive updated interim data from a Phase 1/2 study of ozekibart for advanced colorectal cancer, according to a statement from Transcenta-B.
The planned Biologics License Application (BLA) with the U.S. Food and Drug Administration will be for ozekibart’s use in conventional chondrosarcoma, a type of bone cancer. The separate ongoing trial combines ozekibart with a chemotherapy regimen in patients with metastatic colorectal cancer. Transcenta holds the exclusive rights to develop and commercialize the drug in mainland China, Hong Kong, Macau, and Taiwan.
The dual positive developments for ozekibart significantly advance its path toward potential commercialization. In light of the progress, Transcenta announced it is now “actively evaluating its plans in the Greater China region” for the asset.
The planned BLA submission provides a clear timeline for a potential U.S. market entry, a key catalyst for the drug’s value. Investors will now be watching for Transcenta’s strategic decision on accelerating development and commercialization for the Greater China market, which could unlock a significant new revenue stream.
This article is for informational purposes only and does not constitute investment advice.
